Etherna attracts Series B

Etherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding.

ByIris Dorbian

16 June 2020•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Etherna attracts Series B

Boehringer Ingelheim Venture Fund

Fund+

Omega Funds

Related articles